A randomised Phase II study of carboplatin with or without the addition of the ETAR inhibitor ZD4054 as treatment for patients with metastatic breast cancer.

Trial Profile

A randomised Phase II study of carboplatin with or without the addition of the ETAR inhibitor ZD4054 as treatment for patients with metastatic breast cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Zibotentan (Primary) ; Carboplatin
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms PLANET
  • Most Recent Events

    • 12 Mar 2014 New source identified and integrated, ClinicalTrials.gov: US National Institutes of Health (NCT01134497).
    • 03 May 2012 Status changed from recruiting to discontinued as reported by ISRCTN: Current Controlled Trials record.
    • 06 Aug 2011 New source identified and integrated (United Kingdom Clinical Research Network record).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top